Betaine
Amversio, Betaine, Cystadane (betaine) is a small molecule pharmaceutical. Betaine was first approved as Cystadane on 1996-10-25. It is used to treat homocystinuria in the USA. It has been approved in Europe to treat homocystinuria.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| antibacterial lotions | C200263 | 2024-05-16 |
| anubis barcelona total hydrating | OTC monograph final | 2023-09-01 |
| atono2 oxygen baby | unapproved drug other | 2016-10-13 |
| balmers hanryeoncho w | unapproved drug other | 2015-07-20 |
| betaine | ANDA | 2022-11-04 |
| betaine anhydrous | ANDA | 2023-12-18 |
| betaine anhydrous for oral solution | ANDA | 2020-05-01 |
| celraum pheromone fragrance lovely perfume | unapproved drug other | 2022-10-13 |
| cystadane | New Drug Application | 2023-01-11 |
| dr.bro man of sense mans cleanser | unapproved drug other | 2020-11-25 |
Show 11 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A09: Digestives, incl. enzymes
— A09A: Digestives, incl. enzymes
— A09AB: Acid preparations, digestives
— A09AB02: Betaine hydrochloride
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AA: Amino acids and derivatives
— A16AA06: Betaine
HCPCS
No data
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 2 | 2 | 4 |
| Syndrome | D013577 | — | — | — | — | — | 1 | 2 | 3 |
| Xerostomia | D014987 | — | K11.7 | — | — | 1 | 1 | 1 | 3 |
| Surgical wound infection | D013530 | — | — | — | — | — | 3 | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 2 | — | 2 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | 1 | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 2 | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | 1 | — | 1 |
| Wound infection | D014946 | — | — | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | 1 | — | 2 | 4 |
| Hyperhomocysteinemia | D020138 | — | — | — | 1 | 1 | — | 2 | 4 |
| Hepatitis c | D006526 | — | B19.2 | 1 | 1 | 1 | — | 1 | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 1 | 1 | — | 1 | 3 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | 1 | 1 | — | 1 | 3 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 1 | 1 | — | 1 | 3 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 2 | 1 | — | 1 | 3 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 1 | — | 1 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 1 | 2 |
| Peroxisomal disorders | D018901 | Orphanet_44 | E71.5 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 2 | 3 |
| Overweight | D050177 | — | E66.3 | 1 | 1 | — | — | 2 | 3 |
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | 1 | 2 |
| Micronutrients | D018977 | — | — | — | 1 | — | — | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | — | — | — | 1 |
| Hyperoxaluria | D006959 | — | E72.53 | — | 1 | — | — | — | 1 |
| Primary hyperoxaluria | D006960 | — | E72.53 | — | 1 | — | — | — | 1 |
| Homocystinuria | D006712 | HP_0002156 | E72.11 | — | 1 | — | — | — | 1 |
| Gallbladder diseases | D005705 | EFO_0003832 | K82.9 | — | 1 | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 7 | 9 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | — | — | 2 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 2 | — | — | — | — | 2 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 2 | — | — | — | — | 2 |
| Chronic hepatitis | D006521 | — | K73.9 | 1 | — | — | — | 1 | 2 |
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | — | — | — | 1 | 2 |
| Infertility | D007246 | HP_0000789 | — | 1 | — | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Homozygote | D006720 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wound healing | D014945 | GO_0042060 | — | — | — | — | — | 2 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 2 | 2 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 2 | 2 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | — | — | 1 | 1 |
| Angelman syndrome | D017204 | Orphanet_72 | Q93.51 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 1 | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | — | — | — | 1 | 1 |
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Betaine |
| INN | — |
| Description | N,N,N-trimethylglycinium is a quaternary ammonium ion in which the substituents on nitrogen are methyl (three) and carboxymethyl. It has a role as a fundamental metabolite. It is a conjugate acid of a glycine betaine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)CC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 107-43-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL95889 |
| ChEBI ID | 41139 |
| PubChem CID | 248 |
| DrugBank | DB04455 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34,471 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enlyte
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
883 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use